Several medications work similarly to Ozempic, ranging from other injectable GLP-1 drugs to newer dual- and triple-action therapies that target additional hormones. Some are already available by prescription, while others are in late-stage development. The right alternative depends on whether you’re managing type 2 diabetes, seeking weight loss, or simply looking for a different delivery method like a daily pill instead of a weekly injection.
How Ozempic Works
Ozempic contains semaglutide, a synthetic version of a gut hormone called GLP-1 that your body naturally releases after eating. It slows digestion, reduces appetite, and helps your pancreas release insulin more effectively. Semaglutide is engineered to last long enough in your bloodstream that a single weekly injection maintains steady levels. That basic mechanism, activating the GLP-1 receptor, is shared by every drug in this class. The differences come down to how potent they are, how many hormone receptors they target, and how you take them.
Wegovy: Same Drug, Different Purpose
Wegovy is semaglutide at a higher dose, approved specifically for weight management rather than diabetes. If you’ve heard of both names and wondered what separates them, it’s the indication and the dosing ceiling. Ozempic tops out at a lower maintenance dose intended for blood sugar control, while Wegovy goes higher for greater weight loss. The active ingredient is identical.
Rybelsus: Semaglutide in Pill Form
Rybelsus is the oral tablet version of semaglutide. It comes in 3 mg, 7 mg, and 14 mg strengths, taken once daily on an empty stomach with a small sip of water. You typically start at 3 mg and gradually increase over several months. At the maximum 14 mg daily dose, Rybelsus is roughly equivalent to the 1 mg weekly Ozempic injection. In clinical trials, Ozempic at that dose lowered A1c by about 1.6%, while Rybelsus achieved a 1.4% reduction. The trade-off is convenience versus potency: you avoid needles, but the oral form is slightly less effective and requires strict timing around meals.
Mounjaro: Targeting Two Hormones at Once
Mounjaro (tirzepatide) is the most prominent alternative that goes beyond what Ozempic does. Instead of activating only the GLP-1 receptor, it also activates the GIP receptor, a second gut hormone involved in insulin release and fat metabolism. This dual action produces greater weight loss and blood sugar improvement than semaglutide alone in head-to-head trials.
The engineering behind tirzepatide is interesting. It was built on the GIP hormone’s structure with GLP-1 activity added in, so it binds the GIP receptor with full strength while activating the GLP-1 receptor at roughly half the intensity of Ozempic. Despite that weaker GLP-1 signal, tirzepatide needs less GLP-1 receptor engagement to deliver equivalent or superior results, likely because the two hormones work synergistically. Mounjaro is a weekly injection, like Ozempic, and is approved for type 2 diabetes. A higher-dose version called Zepbound is approved for weight loss.
Saxenda: A Daily GLP-1 Injection
Saxenda contains liraglutide, an older GLP-1 drug that requires a daily injection rather than a weekly one. It’s approved for weight management. Because liraglutide doesn’t last as long in the body as semaglutide, you need that daily dose to maintain its effects. The same molecule, at a lower dose under the brand name Victoza, is used for type 2 diabetes. Saxenda produces meaningful weight loss, but clinical comparisons generally show semaglutide delivers more. For people who respond poorly to semaglutide or experience side effects specific to it, liraglutide remains a well-established option.
CagriSema: Adding an Appetite Hormone
CagriSema combines semaglutide with cagrilintide, a long-acting version of amylin, another hormone your pancreas releases alongside insulin after meals. Amylin slows stomach emptying and signals fullness through different brain pathways than GLP-1 does. By pairing both hormones, the combination targets appetite from two directions. In a 68-week trial of adults with overweight or obesity and type 2 diabetes, CagriSema produced an average weight loss of 13.7%, compared to 3.4% with placebo. This combination is not yet approved but is in late-stage clinical trials.
Retatrutide: A Triple-Action Drug
Retatrutide takes the multi-receptor concept further by targeting three hormone receptors: GLP-1, GIP, and glucagon. Adding glucagon, a hormone that raises blood sugar and increases energy expenditure, seems counterintuitive, but at the right dose it boosts calorie burning and fat breakdown without destabilizing blood sugar, because the GLP-1 and GIP components counterbalance it. In a phase 2 trial, participants lost an average of 17.5% of their body weight at 24 weeks and 24.4% at 48 weeks, numbers that exceed what any currently approved medication has achieved. Phase 3 trials are underway.
Orforglipron: A Next-Generation Pill
Orforglipron is a daily oral GLP-1 drug with one key advantage over Rybelsus: it’s a small molecule rather than a peptide, which means it doesn’t require the empty-stomach, limited-water routine that makes Rybelsus inconvenient. You take it once daily without food or water restrictions. A completed phase 3 trial compared orforglipron directly to oral semaglutide in adults with type 2 diabetes, and results are being reviewed. If approved, it could become the most practical oral option in this class.
Berberine and Other Supplements
Berberine, a plant compound sold as a supplement, gained attention on social media as “nature’s Ozempic.” The comparison is misleading. While berberine has some effect on blood sugar through mechanisms loosely similar to metformin, there is little evidence it directly increases feelings of fullness the way GLP-1 drugs do. Clinical data shows berberine produces modest weight reductions of roughly 4 to 9 pounds, with many trials showing little to no effect. That’s a fraction of the roughly 10% or more body weight loss seen with prescription GLP-1 medications. A dose of around 1,000 mg per day has shown some benefit for BMI when taken for at least two months, but berberine is not a substitute for semaglutide in any clinical sense.
Comparing the Options at a Glance
- Wegovy/Zepbound: Prescription, weekly injection, approved for weight loss. Wegovy uses semaglutide; Zepbound uses tirzepatide.
- Rybelsus: Prescription, daily pill, same drug as Ozempic but slightly less effective at max dose.
- Mounjaro: Prescription, weekly injection, dual-action (GLP-1 plus GIP), approved for type 2 diabetes.
- Saxenda: Prescription, daily injection, older GLP-1 drug, approved for weight loss.
- CagriSema: Not yet approved, combines semaglutide with an amylin-based drug for enhanced weight loss.
- Retatrutide: Not yet approved, triple-action drug with the highest weight loss seen in trials so far.
- Orforglipron: Not yet approved, daily pill without food restrictions.
- Berberine: Over-the-counter supplement, minimal weight loss compared to prescription drugs.
The landscape of GLP-1 drugs is expanding quickly. For people already on Ozempic who want something different, the practical choices today are Rybelsus for an oral option, Mounjaro or Zepbound for potentially stronger results, and Saxenda for a different GLP-1 molecule. Within the next few years, combination and triple-action therapies could significantly raise the bar for what these medications can achieve.